StreetInsider.com News Articles

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'

Tue, 01 Sep 2026 06:31:05 -0400

(Updated - September 1, 2026 6:31 AM EDT)

Piper Sandler analyst Edward Tenthoff upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Overweight with a price target of $25.00.

The analyst comments "We are upgrading Capricor to Overweight from Neutral and increasing our price target to $25 from $2. Last week, the FDA extended the PDUFA date for deramiocel to November 22nd after CBER accepted a major BLA amendment comprised of 24-month HOPE-3 OLE data and a request for a refined indication of upper limb function. As published in The Lancet, absolute decrease in PUL2.0 was 1.2 points less with deramiocel than placebo

Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'

Tue, 01 Sep 2026 06:31:05 -0400

(Updated - September 1, 2026 6:31 AM EDT)

Piper Sandler analyst Edward Tenthoff upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Overweight with a price target of $25.00.

Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'

Tue, 01 Sep 2026 06:31:05 -0400

(Updated - September 1, 2026 6:31 AM EDT)

Piper Sandler analyst Edward Tenthoff upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Overweight with a price target of $25.00.

Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'

Tue, 01 Sep 2026 06:31:05 -0400

(Updated - September 1, 2026 6:31 AM EDT)

Piper Sandler analyst Edward Tenthoff upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Overweight with a price target of $25.00.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Mon, 31 Aug 2026 13:10:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 31, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of California.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Mon, 31 Aug 2026 13:10:00 -0400

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 28 Aug 2026 17:48:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 28, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 28 Aug 2026 17:48:00 -0400

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 26 Aug 2026 21:38:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 26, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 26 Aug 2026 21:38:00 -0400

Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'

Tue, 25 Aug 2026 06:58:23 -0400

(Updated - August 25, 2026 6:58 AM EDT)

Oppenheimer analyst Leland Gershall upgraded Capricor Therapeutics (NASDAQ: CAPR) from Perform to Outperform, PT $54.00.

The analyst comments "We upgrade to Outperform with $54 PT on yesterday's regulatory update and further color from our follow-up call with CEO Linda Marbán. Driving our constructive outlook is the FDA's acceptance of material submitted since last month's ad comm as a major amendment (PDUFA date now 11/22) together with the signal that the agency may consider an upper limb function-based Duchenne indication—one that would align with the Phase 3 trial's primary endpoint, for which efficacy appears less